These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18391834)

  • 21. Low-dose oral or non-oral hormone therapy: effects on C-reactive protein and atrial natriuretic peptide in menopause.
    Casanova G; dos Reis AM; Spritzer PM
    Climacteric; 2015 Feb; 18(1):86-93. PubMed ID: 25017924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacology of different progestogens: the special case of drospirenone.
    Sitruk-Ware R
    Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.
    Karara AH; Hanes V; Alonso A; Ni P; Poola N; Silang R; Blode H; Preston RA
    J Clin Pharmacol; 2007 Oct; 47(10):1292-302. PubMed ID: 17906162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estradiol + drospirenone.
    Prescrire Int; 2007 Jun; 16(89):106. PubMed ID: 17590905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
    Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
    Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progestin may modify the effect of low-dose hormone therapy on mammographic breast density.
    Panoulis C; Lambrinoudaki I; Vourtsi A; Augoulea A; Kaparos G; Aravantinos L; Christodoulakos G; Creatsas G
    Climacteric; 2009 Jun; 12(3):240-7. PubMed ID: 19387881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of hormone therapy on vocal quality in postmenopausal women.
    D'haeseleer E; Depypere H; Claeys S; Baudonck N; Van Lierde K
    J Voice; 2012 Sep; 26(5):671.e1-7. PubMed ID: 22578434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical application of antialdosterone-containing hormone therapy for postmenopausal women.
    Minkin MJ
    J Reprod Med; 2007 Feb; 52(2 Suppl):165-8. PubMed ID: 17477111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study.
    Gambacciani M; Rosano G; Cappagli B; Pepe A; Vitale C; Genazzani AR
    Climacteric; 2011 Feb; 14(1):18-24. PubMed ID: 20979461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B-type natriuretic peptide after hormone therapy in postmenopausal women with chest pain and normal coronary angiogram.
    Kawano H; Nagayoshi Y; Soejima H; Tanaka Y; Hokamaki J; Miyamoto S; Miyazaki Y; Yamabe H; Ogawa H
    Menopause; 2008; 15(2):352-6. PubMed ID: 18090872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose estrogen and drospirenone combination: effects on glycoinsulinemic metabolism and other cardiovascular risk factors in healthy postmenopausal women.
    Villa P; Suriano R; Ricciardi L; Tagliaferri V; De Cicco S; De Franciscis P; Colacurci N; Lanzone A
    Fertil Steril; 2011 Jan; 95(1):158-63. PubMed ID: 20728082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drospirenone in HRT?
    Drug Ther Bull; 2009 Apr; 47(4):41-4. PubMed ID: 19357298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coadministration of estradiol/drospirenone and indomethacin does not cause hyperkalemia in healthy postmenopausal women: a randomized open-label crossover study.
    Schütt B; Kunz M; Blode H
    J Clin Pharmacol; 2007 Jun; 47(6):774-81. PubMed ID: 17463217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of raloxifene on the vaginal epithelium of postmenopausal women.
    Delmanto A; Nahas-Neto J; Nahas EA; de Oliveira ML; Fernandes CE; Traiman P
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):187-92. PubMed ID: 18400357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17β-estradiol in postmenopausal women with moderate to severe vasomotor symptoms.
    Sutter G; Schmelter T; Gude K; Schaefers M; Gerlinger C; Archer DF
    Menopause; 2014 Mar; 21(3):236-42. PubMed ID: 23963309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.
    Rübig A
    Climacteric; 2003 Oct; 6 Suppl 3():49-54. PubMed ID: 15018248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytological aspects of the nasal respiratory epithelium in reproductive-age women taking oral contraceptives.
    Caruso S; Serra A; Maiolino L; Agnello C; Di Mari L; Ruta S; Arcidiacono A; Cianci A
    Eur J Contracept Reprod Health Care; 2006 Dec; 11(4):250-7. PubMed ID: 17484189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension.
    White WB
    Climacteric; 2007 Feb; 10 Suppl 1():25-31. PubMed ID: 17364595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of estradiol valerate and levonorgestrel on vaginal health.
    Manonai J; Chittacharoen A; Theppisai U
    Eur J Obstet Gynecol Reprod Biol; 2004 Aug; 115(2):190-3. PubMed ID: 15262354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.